ESMO shared on LinkedIn:
“For ESMO members: Breaking Science in Gastrointestinal Cancers.
Michel P. Ducreux presents his findings on Sequences of regorafenib and trifluridine/tipiracil after failure of standard therapies for mCRC.
Explore this video and the entire series on OncologyPRO now.”
Source: ESMO/LinkedIn